Anna Honko
Overview
Explore the profile of Anna Honko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bohler F, Cashman K, Wilkinson E, Johnson J, Rosenke K, Shamblin J, et al.
Front Cell Infect Microbiol
. 2024 Feb;
14:1341891.
PMID: 38404292
Lassa virus (LASV) causes an acute multisystemic hemorrhagic fever in humans known as Lassa fever, which is endemic in several African countries. This manuscript focuses on the progression of disease...
2.
Chang M, Ke H, Losada Miguens L, Coherd C, Nguyen K, Kamkaew M, et al.
Protein Eng Des Sel
. 2023 Aug;
36.
PMID: 37561410
Monoclonal antibody (mAb) therapies have rapidly become a powerful class of therapeutics with applications covering a diverse range of clinical indications. Though most widely used for the treatment of cancer,...
3.
Pittman P, Martin J, Mbala Kingebeni P, Tamfum J, Mwema G, Wan Q, et al.
PLoS Negl Trop Dis
. 2023 Apr;
17(4):e0010384.
PMID: 37079637
We describe the results of a prospective observational study of the clinical natural history of human monkeypox (mpox) virus (MPXV) infections at the remote L'Hopital General de Reference de Kole...
4.
Cross R, Longini I, Becker S, Bok K, Boucher D, Carroll M, et al.
PLoS Pathog
. 2022 Oct;
18(10):e1010805.
PMID: 36227853
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming...
5.
Chang M, Tomasovic L, Kuzmina N, Ronk A, Byrne P, Johnson R, et al.
Nat Commun
. 2022 Oct;
13(1):5814.
PMID: 36192374
Monoclonal antibodies are a promising approach to treat COVID-19, however the emergence of SARS-CoV-2 variants has challenged the efficacy and future of these therapies. Antibody cocktails are being employed to...
6.
Downs I, Johnson J, Rossi F, Dyer D, Saunders D, Twenhafel N, et al.
Viruses
. 2021 Nov;
13(11).
PMID: 34835103
Ebola virus disease (EVD) is a serious global health concern because case fatality rates are approximately 50% due to recent widespread outbreaks in Africa. Well-defined nonhuman primate (NHP) models for...
7.
Ai X, Wang D, Honko A, Duan Y, Gavrish I, Fang R, et al.
J Am Chem Soc
. 2021 Oct;
143(42):17615-17621.
PMID: 34647745
Cellular binding and entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are mediated by its spike glycoprotein (S protein), which binds with not only the human angiotensin-converting enzyme 2...
8.
Langellotto F, Dellacherie M, Yeager C, Ijaz H, Yu J, Cheng C, et al.
Adv Healthc Mater
. 2021 Oct;
10(22):e2101370.
PMID: 34605223
The coronavirus disease 2019 (COVID-19) pandemic demonstrates the importance of generating safe and efficacious vaccines that can be rapidly deployed against emerging pathogens. Subunit vaccines are considered among the safest,...
9.
Davis S, Milechin L, Patel T, Hernandez M, Ciccarelli G, Samsi S, et al.
Front Physiol
. 2021 Sep;
12():691074.
PMID: 34552498
Early warning of bacterial and viral infection, prior to the development of overt clinical symptoms, allows not only for improved patient care and outcomes but also enables faster implementation of...
10.
Zabaleta N, Dai W, Bhatt U, Herate C, Maisonnasse P, Chichester J, et al.
Cell Host Microbe
. 2021 Aug;
29(9):1437-1453.e8.
PMID: 34428428
The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that...